Difference between revisions of "Glucarpidase (Voraxaze)"
(updated package insert links) |
m |
||
| Line 1: | Line 1: | ||
| − | |||
==General information== | ==General information== | ||
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf Glucarpidase (Voraxaze) package insert at FDA.gov]</ref><ref>[http://www.btgplc.com/document/442 Glucarpidase (Voraxaze) package insert at BTG]</ref><ref>[[Media:Glucarpidase.pdf|Glucarpidase (Voraxaze) package insert (locally hosted backup)]]</ref><ref>[http://www.btgplc.com/products/specialty-pharmaceuticals/voraxaze Glucarpidase (Voraxaze) manufacturer's website]</ref> | Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.<ref name="insert">[http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf Glucarpidase (Voraxaze) package insert at FDA.gov]</ref><ref>[http://www.btgplc.com/document/442 Glucarpidase (Voraxaze) package insert at BTG]</ref><ref>[[Media:Glucarpidase.pdf|Glucarpidase (Voraxaze) package insert (locally hosted backup)]]</ref><ref>[http://www.btgplc.com/products/specialty-pharmaceuticals/voraxaze Glucarpidase (Voraxaze) manufacturer's website]</ref> | ||
| Line 10: | Line 9: | ||
*[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/glucarpidase-patient-drug-information Glucarpidase (Voraxaze) patient drug information (UpToDate)]</ref> | ||
*Brief patient counseling information can be found on the last page of the [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf#page=11 package insert].<ref name="insert"></ref> | *Brief patient counseling information can be found on the last page of the [http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125327lbl.pdf#page=11 package insert].<ref name="insert"></ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 1/17/2012: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy protective agents]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2012]] | ||
Revision as of 14:30, 3 November 2014
General information
Class/mechanism: Recombinant bacterial enzyme that degrades folic acid and antifolates such as methotrexate by hydrolyzing their carboxyl-terminal glutamate residues. Glucarpidase catalyzes the degradation of methotrexate to the inactive metabolites 4-deoxy-4-amino-N10-methylpteroic acid (DAMPA) and glutamate.[1][2][3][4]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Glucarpidase (Voraxaze) patient drug information (UpToDate)[5]
- Brief patient counseling information can be found on the last page of the package insert.[1]
History of changes in FDA indication
- 1/17/2012: Initial FDA approval